PNPLA3 and metabolic dysfunction-associated steatotic liver disease: This transition into an activated HSCs is marked by the initiation of changes in gene expression of multiple signalling molecules and pathways [45], with the genetic PNPLA3 polymorphism I148M exacerbating the development and progression of MASLD towards MASH.